Last Week in Biotech: Late-Stage Clinical Wins, Multi-Billion Strategic Alliances, and Precision Epigenomic Editing (2026-11-17)

Key biotech developments: Sellas’ Phase 3 AML win, CG Oncology’s oncolytic virus data, Eli Lilly’s $5.9B Stipple deal, J&J’s $2.2B Ollin acquisition, and breakthrough CRISPR enhancer activation.

Share
Last Week in Biotech: Late-Stage Clinical Wins, Multi-Billion Strategic Alliances, and Precision Epigenomic Editing (2026-11-17)
Photo by MJH SHIKDER / Unsplash

Executive Takeaway

The biotechnology and life sciences landscape witnessed significant momentum across oncology clinical readouts, capital deployment, and molecular engineering platforms. Registrational late-stage trials in hematology and bladder oncology demonstrated clinically meaningful survival and recurrence benefits, reinforcing non-chemotherapeutic approaches in maintenance settings. Simultaneously, multi-billion-dollar licensing and M&A transactions underscored the pharmaceutical industry’s aggressive push toward computational epitope discrimination and novel multi-specific biologics.

At the technological frontier, genomic medicine continues to transition from blunt gene-disruption tools to precision dosage modulation and systemic in vivo targeting. The intersection of non-viral targeted delivery, enhancer-directed epigenetic modulation, and high-resolution spatial multi-omics is redefining how researchers approach untreatable monogenic conditions, preinvasive malignancies, and degenerative aging pathways.

Key Sourced Clinical, Translational & Commercial Developments

1. Sellas Life Sciences Phase 3 REGAL Trial Delivers 9-Month Overall Survival Benefit in AML

Sellas Life Sciences announced that its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS)—an investigational peptide immunotherapy directed against Wilms’ tumor 1 (WT1)—met its primary endpoint in acute myeloid leukemia (AML) patients in second complete remission who were ineligible for allogeneic stem cell transplantation. GPS achieved a median overall survival (OS) of 24.0 months compared to less than 15.0 months for best available therapy, reflecting a 41% reduction in the risk of death (hazard ratio = 0.59). The study concluded upon reaching the prespecified 80 death events, prompting Sellas to initiate an accelerated Biologics License Application (BLA) filing with the U.S. FDA.

Strategic Significance: Post-remission maintenance in transplant-ineligible AML has historically yielded poor durability. A statistically significant 9-month OS extension validates peptide-directed cancer vaccines in hematologic indications. (Source)

2. Marrow Therapeutics Launches with $173M to Advance In Vivo Transferrin Bioconjugates

Marrow Therapeutics launched with $173 million in cumulative financing, including a $120 million Series B led by OrbiMed and a $54 million Series A co-led by Scion Life Sciences and venBio. The company's lead candidate, MAR-101, deploys a transferrin antibody-oligonucleotide bioconjugate engineered to home directly to hematopoietic stem and progenitor cells (HSPCs) in the bone marrow niche to silence BCL11A, stimulating fetal hemoglobin synthesis for sickle cell disease and transfusion-dependent beta-thalassemia.

Strategic Significance: Approved cell and gene therapies (e.g., Casgevy) mandate toxic myeloablative busulfan conditioning and apheresis infrastructure. An intravenous, non-viral conjugate targeting bone marrow HSPCs directly bypasses conditioning and hospital-bound ex vivo manufacturing. (Source)

3. Eli Lilly Inks $5.9B Strategic Alliance with Stipple Bio for AI-Guided Epitope Mapping

Eli Lilly entered a multi-target research collaboration and licensing pact valued at up to $5.9 billion in upfront fees and milestone commitments with Stipple Bio. Stipple’s "Pointillist" platform leverages spatial proteomics and machine learning algorithms to map cancer-restricted conformational epitopes and cell-surface proteoforms absent on healthy tissue.

Strategic Significance: The therapeutic window of targeted biologics (ADCs, bispecific T-cell engagers) is frequently narrowed by on-target, off-tumor toxicity against low-level normal tissue expression. AI-driven discrimination of tumor-restricted conformational neoepitopes directly addresses this clinical hurdle. (Source)

4. CG Oncology Phase 3 PIVOT-006 Trial Shows 68% Recurrence Reduction in Bladder Cancer

CG Oncology announced top-line findings from its 367-patient Phase 3 PIVOT-006 study evaluating cretostimogene grenadenorepvec as an adjuvant intravesical monotherapy in intermediate-risk, high-grade Ta non-muscle invasive bladder cancer (NMIBC) post-transurethral resection. Cretostimogene—an engineered conditionally replicating oncolytic adenovirus encoding human GM-CSF—demonstrated a statistically significant 68% relative risk reduction in tumor recurrence over 17 months of follow-up compared to observation alone, with no systemic grade ≥3 adverse events. CG plans two BLA submissions in early 2027.

Strategic Significance: Amid chronic shortages of Bacillus Calmette-Guérin (BCG), an off-the-shelf oncolytic viral vector provides a bladder-sparing therapeutic alternative for high-recurrence patients. (Source)

5. Johnson & Johnson Acquires Ollin Biosciences for $2.2B with $750M Blackstone Co-Funding

Johnson & Johnson executed an agreement to acquire Ollin Biosciences for $2.2 billion upfront and up to $1.125 billion in milestones, securing OLN324, a bispecific antibody targeting VEGF-A and Ang-2 in-licensed from Innovent Biologics. Concurrently, J&J established a risk-sharing arrangement with Blackstone Life Sciences, which will provide $750 million to fund four pivotal Phase 3 registrational studies in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Strategic Significance: Capitalizing on the clinical validation established by dual-pathway retinal biologics, this mega-transaction positions J&J to contest market share while utilizing private equity co-funding to manage late-stage development burn. (Source)

6. Eli Lilly Acquires Mutant CALR Pioneer Calytrix Bio for Up to $1.5B

Eli Lilly agreed to acquire Calytrix Bio—incubated by J.P. Morgan's life sciences venture unit—for up to $1.5 billion in upfront and milestone payments. Calytrix’s lead asset is a preclinical biparatopic antibody targeting mutant calreticulin (mCALR), a driver mutation in roughly 25% of essential thrombocythemia and primary myelofibrosis cases.

Strategic Significance: Unlike existing symptomatic therapies (such as JAK inhibitors), selectively targeting mCALR aims to deplete the underlying neoplastic clone without impairing wild-type hematopoiesis. (Source)

7. Biogen Partners with TrimTech Therapeutics in $411M TRIM21 Targeted Degradation Pact

Biogen entered into a multi-target research collaboration with TrimTech Therapeutics valued at up to $411 million ($32 million upfront and near-term milestones) to utilize TrimTech’s TRIM21-directed protein degradation platform (TRIMTACs and TRIMGLUEs). The alliance targets pathological neurotoxic aggregate clearance across Alzheimer’s, Parkinson’s, and Huntington’s diseases.

Strategic Significance: Classic PROTACs rely predominantly on CRBN or VHL ligases, which face tissue specificity limits and resistance mutations. Harnessing the intracellular antibody receptor TRIM21 provides an alternative proteasomal route to degrade intracellular neurodegenerative targets. (Source)

8. China Tightens Gene-Editing Governance Following Sanctions in Fatal IIT Trial

Chinese health and scientific authorities terminated two senior biomedical investigators and enacted a five-year ban on state research funding following an investigation into a pediatric death during an investigator-initiated trial (IIT) of an experimental in vivo gene therapy. Investigators were found to have suppressed preclinical safety red flags, omitted death risks from parental consent, concealed the fatality from academic publication, and accepted undisclosed gifts. China’s National Health Commission issued nationwide curbs on hospital-based IIT approvals.

Strategic Significance: Hospital-based IIT agility has historically accelerated early-phase gene-editing translation in China. Stricter centralized regulatory oversight harmonizes regional development with global standards but may temper early-stage clinical trial velocity. (Source)

9. Enhancer-Targeted CRISPR Activation Rescues Gene Dosage in Autism Organoid Model

UCLA investigators published findings in Nature Neuroscience showing that an enhancer-targeted CRISPR activation (eCRISPR-A) platform restored haploinsufficient TCF4 expression to physiological levels in cortical organoids and mouse models of Pitt-Hopkins syndrome. By targeting non-coding regulatory enhancer elements using dCas9 fused to transactivators, the team normalized transcription of the intact allele without inducing supra-physiological overexpression, rescuing neural firing and synaptic architecture.

Strategic Significance: Haploinsufficient disorders risk toxicity under conventional cDNA overexpression. Epigenomic enhancer tuning presents an endogenous dosage-controlled blueprint for complex monogenic central nervous system conditions. (Source)

10. Superb-seq Method Maps Single-Cell Transcriptomic Consequences of Cas9 Edits

Salk Institute researchers published "Superb-seq" in Nature Methods, a technology that simultaneously resolves genomic on- and off-target cleavage events and whole-transcriptome expression within identical single cells. The study revealed that even infrequent off-target double-strand breaks provoke persistent p53 checkpoint activation and non-canonical interferon signaling obscured in bulk sequencing assays.

Strategic Significance: As global regulators heighten stringency around off-target characterization, linking sequence-level mis-cleavage directly to functional transcriptomic stress responses establishes an enhanced analytical release standard. (Source)

11. Synthetic Biology: Commensal Microbes Engineered to Deconjugate Bile Acids Reverse Metabolic Aging

UC San Diego researchers reported in Cell Metabolism that centenarians harbor an enriched gut microbiome marked by elevated bile salt hydrolase (BSH) activity. Engineering native murine commensals to constitutively express BSH and administering them orally to 82-week-old mice achieved stable colonization, reversing insulin resistance, reducing adiposity, and restoring youthful metabolic and circadian transcription programs over a 32-week period.

Strategic Significance: Highlights the shift from whole-fecal microbiota transplants toward engineered native living biotherapeutic products (LBPs) delivering continuous localized metabolic modulation. (Source)

12. MD Anderson Constructs Spatial and Single-Cell Atlas of Preinvasive DCIS

A multi-disciplinary team at MD Anderson published in Science an architectural and single-cell atlas mapping ductal carcinoma in situ (DCIS) progression. The spatial dataset resolved focal disruptions in myoepithelial integrity, matrix collagen reorganization, and localized CD8+ T-cell exclusion driven by specific cancer-associated fibroblast subsets that differentiate invasive trajectories from indolent lesions.

Strategic Significance: Overdiagnosis and overtreatment of indolent DCIS remain major clinical burdens. Spatial multi-omics provides computational classifiers to enable safe active surveillance protocols. (Source)

  • Transition to In Vivo & Epigenetic Precision: The shift from ex vivo cell therapies to non-viral systemic targeting (e.g., Marrow's HSPC bioconjugates) and enhancer-targeted CRISPR-A reflects a broader push toward lower manufacturing complexity and endogenous dosage regulation.
  • Targeted Biologics Beyond Canonical Ligases: Biogen's investment in TRIM21 and Lilly's mCALR buyout show the biopharma industry moving past standard PROTAC ligases and unselective pathway inhibitors into clone-specific and organelle-directed modalities.
  • Spatial Proteomics & Single-Cell Quality Control: Stipple's platform deal and the Superb-seq publication highlight that spatial epitope accuracy and single-cell cellular stress profiling are becoming core gating requirements in bio-AI drug design and regulatory dossiers.

Practical Implications for Bio-engineers, Researchers & Healthcare Enterprises

  • Translational Biologists: Consider non-coding enhancer elements over primary promoters when designing CRISPR activation constructs for haploinsufficient neurodevelopmental targets to prevent over-expression toxicity.
  • CMC and Analytical Teams: Prepare for regulatory requests requiring single-cell transcriptomic stress evaluations (such as p53 pathway activation) alongside deep-sequencing off-target panels for CRISPR IND filings.
  • Corporate Development: Private equity risk-sharing models (as seen in J&J’s partnership with Blackstone Life Sciences) offer a viable blueprint to offload clinical development expenditures in late-stage Phase 3 registrational programs.

What to Watch in the Coming Week

  • Regulatory follow-ups and BLA submission timelines for Sellas’ galinpepimut-S in acute myeloid leukemia and CG Oncology’s cretostimogene in high-grade NMIBC.
  • Further institutional policy updates from regional regulators regarding oversight of investigator-initiated trials for in vivo gene therapy.
  • Preclinical safety and pharmacokinetic disclosures from early-stage bone-marrow-homing oligonucleotide conjugate programs.